Disease · MONDO_0005040
Comparisons in its trials19
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 19 of 19
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Group A: <= 6 Cycles of Cisplatin vs Group: B > 6 Cycles of Cisplatin: serious adverse events | 7 of 92 | 2 of 16 | 108 | NCT00002558 | Trial comparisons |
| Cohort 1: HD GeM-DMC+ ICE + Bevacizumab for Refractory GCT vs Cohort 2: HD GeM-DMC+ ICE for Refractory GCT: Number of Participants With 2-year Event-Free Survival (EFS) | 28 of 41 | 11 of 23 | 64 | NCT00936936 | Trial comparisons |
| Cohort 1: HD GeM-DMC+ ICE + Bevacizumab for Refractory GCT vs Cohort 2: HD GeM-DMC+ ICE for Refractory GCT: deaths from any cause | 22 of 41 | 12 of 23 | 64 | NCT00936936 | Trial comparisons |
| Cohort 1: HD GeM-DMC+ ICE + Bevacizumab for Refractory GCT vs Cohort 2: HD GeM-DMC+ ICE for Refractory GCT: Overall Survival | 25 of 41 | 9 of 23 | 64 | NCT00936936 | Trial comparisons |
| Cohort 1: HD GeM-DMC+ ICE + Bevacizumab for Refractory GCT vs Cohort 2: HD GeM-DMC+ ICE for Refractory GCT: serious adverse events | 7 of 41 | 2 of 23 | 64 | NCT00936936 | Trial comparisons |
| Stage 1: ARQ 197 360 mg BID vs Total: deaths from any cause | 0 of 21 | 0 of 27 | 48 | NCT01055067 | Trial comparisons |
| Stage 1: ARQ 197 360 mg BID vs Total: serious adverse events | 6 of 21 | 9 of 27 | 48 | NCT01055067 | Trial comparisons |
| Part A (Alvocidib and Oxaliplatin) vs Part B (Alvocidib and FOLFOX): serious adverse events | 4 of 7 | 7 of 29 | 36 | NCT00957905 | Trial comparisons |
| 2 Transplants vs 1 Transplant: Numbers of Patients Unable to Mobilize Peripheral Blood Stem Cells | 0 of 14 | 0 of 9 | 23 | NCT00432094 | Trial comparisons |
| 2 Transplants vs 1 Transplant: Engraftment of Platelets | 13 of 14 | 8 of 9 | 23 | NCT00432094 | Trial comparisons |
| 2 Transplants vs 1 Transplant: Engraftment of Neutrophils | 13 of 14 | 9 of 9 | 23 | NCT00432094 | Trial comparisons |
| Regimen A (Radiotherapy Only) vs Regimen B (Chemotherapy Plus Radiotherapy): serious adverse events | 0 of 10 | 0 of 12 | 22 | NCT00085098 | Trial comparisons |
| CD30 Negative/Unknown vs CD30 Positive: Number of Patients With Treatment Related Adverse Events Grade 3 or Above | 0 of 11 | 2 of 7 | 18 | NCT02689219 | Trial comparisons |
| CD30 Negative/Unknown vs CD30 Positive: deaths from any cause | 8 of 11 | 6 of 7 | 18 | NCT02689219 | Trial comparisons |
| CD30 Negative/Unknown vs CD30 Positive: serious adverse events | 2 of 11 | 3 of 7 | 18 | NCT02689219 | Trial comparisons |
Phase I Dose Level 1 Mithramycin 60 mcg/kg vs Phase I Dose Level -1 Mithramycin 60 mcg/kg Followed by Mithramycin 30 mcg/kg: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 1 of 1 | 2 of 2 | 3 | NCT02859415 | Trial comparisons |
| Phase I Dose Level 1 Mithramycin 60 mcg/kg vs Phase I Dose Level -1 Mithramycin 60 mcg/kg Followed by Mithramycin 30 mcg/kg: deaths from any cause | 0 of 1 | 0 of 2 | 3 | NCT02859415 | Trial comparisons |
| Phase I Dose Level 1 Mithramycin 60 mcg/kg vs Phase I Dose Level -1 Mithramycin 60 mcg/kg Followed by Mithramycin 30 mcg/kg: Number of Participants With a Dose-limiting Toxicity (DLT) | 0 of 1 | 0 of 2 | 3 | NCT02859415 | Trial comparisons |
| Phase I Dose Level 1 Mithramycin 60 mcg/kg vs Phase I Dose Level -1 Mithramycin 60 mcg/kg Followed by Mithramycin 30 mcg/kg: serious adverse events | 0 of 1 | 2 of 2 | 3 | NCT02859415 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005040/comparisons